Mechanisms regulating cytomegalovirus

巨细胞病毒的调节机制

基本信息

  • 批准号:
    10047701
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-10-01 至 2022-09-30
  • 项目状态:
    已结题

项目摘要

Human cytomegalovirus (HCMV) infects over half of all Veterans and threatens the lives of those with impaired immune systems. Even among Veterans with normal immune systems, the insidious reactivation of the virus taxes the immune system, incites low-level inflammation, and possibly accelerates aging and shortens lifespan. HCMV is the most common infectious cause of birth defects. There is no HCMV vaccine and the antiviral drugs have problems with potency, toxicity, and drug-resistance. The long-range goal of this research is to identify critical pivot points in the viral transcription-DNA replication cycle that are vulnerable new targets for therapeutic intervention. This proposal is based on the premise that our gap in knowledge of how viral early transcription begets viral DNA replication and viral DNA replication begets viral late transcription limits our ability to design therapeutic treatments for the viral disease. We have developed modified PRO-Seq and PRO-Cap methods to determine exactly where on the viral genome that Pol II and its attached nascent transcript is located and at what frequency the engaged Pol II is at that nucleotide position during the infection. This allows us to precisely determine where transcription is initiating, the extent of promoter-proximal Pol II pausing, and the degree to which productive transcription elongation is taking place. We designed bioinformatics algorithms to analyze this data. Our preliminary studies show that HCMV utilizes host Pol II elongation control in early and late infection, but HCMV evolved different strategies in promoting the viral transcription and linking it to viral DNA replication. Frequently used viral promoters more often contain upstream TATA elements than do host promoters and viral initiator elements differ from that of the host in nucleotide preference. In late infection, HCMV and not the host uses TATT as a Pol II positioning element, which presumably requires the actions of viral late transcription factors (LTFs). We also find that nearly 20% of paused Pol II is found in the non-coding long RNA4.9 gene at a location in the viral lytic origin of replication (oriLyt) that is essential for oriLyt function; robust enhancer transcription underlies the world renown viral major immediate-early promoter; and viral transcription is pervasive and exhibits a pattern predictive of that arising from an unchromatinzed DNA template. Our research plan is designed to further validate, establish meaning of, and mechanistically understand these findings. To advance these objectives, we have adapted a newly developed approach to specifically and rapidly deplete viral proteins putatively involved in viral transcription. As proof of concept, we observe changes in levels of multiple viral RNAs after eliminating all the viral IE2 protein isoforms in late infection over a 6-hr timeframe, suggesting that the actions of one or more of these viral protein isoforms may have an overarching effect on viral transcription. We will combine this technique with PRO-Seq and PRO-Cap to determine the roles of the IE2 isoforms and the UL79 LTF (a putative late viral transcription elongation factor) in viral late transcription. In doing these studies, we will test the hypothesis that HCMV usurps Pol II initiation and elongation control to direct viral DNA replication, coordinate the virus’s gene expression program in lytic and latent-like infections, and contend with the threat of chromatin invasion. Our studies have been specifically designed to determine the role of transcription and structural elements in the function of the HCMV replication origin (Aim 1); determine the core DNA elements and viral factors required in late viral transcription (Aim 2); and determine how transcription differs in a quiescent infection and responds to activation (Aim 3). This proposal integrates the pertinent and extensive expertise of the Meier and the Price labs in virology and transcription, respectively. This research could not be done by either lab alone. The Meier and Price labs have a strong foundation of productive collaboration on which to build and complete this research plan.
人类巨细胞病毒(HCMV)感染了所有退伍军人的一半以上,并威胁 免疫系统受损。 病毒征税的免疫系统,煽动低水平的炎症,并可能加速衰老和 缩短寿命。 抗毒药的耐药性和抗药性问题 这项研究是为了确定病毒转录-DNA复制周期中的关键枢轴点 脆弱的治疗干预目标。 了解病毒早期转录如何使病毒DNA复制和病毒DNA复制成为病毒 晚期转录限制了我们对病毒疾病的能力治疗 修改了Pro-Seq和Pro-CAP方法,以确定Pol II和Pol II和 它的新生转录本位于 - AT -AT -the II。 感染期间的位置。 促进剂pol II的暂停以及生产伸长的程度 我们设计了生物信息学算法来分析我们的初步研究 在早期和晚期感染中利用宿主的pol II伸长控制,但HCMV发展了不同的策略 促进病毒转录并将其与病毒DNA复制联系起来。 通常包含上游塔塔元素的元素,而宿主启动子和病毒引发剂元素与of 核苷酸偏好中的宿主,HCMV和宿主使用TATT作为POL II定位 元素可能需要病毒晚期转录因子的作用(LTF)。 在病毒裂解起源的某个位置,在非编码长的长RNA4.9基因中发现了近20%的暂停POL II 对Orlyt功能至关重要的复制(Orlyt); 流行的主要立即启动子和病毒转录是普遍的 预测由未染色的DNA模板引起的。 验证,建立含义并理解这些发现,以提高这些目标, 我们已经改编了一种新开发的方法来专门,迅速耗尽病毒蛋白; 参与病毒转录作为概念证明,我们观察到多个病毒RNA的水平 在6小时的时间范围内消除晚期感染中所有病毒IE2蛋白同工型,建议您 一种或多种病毒蛋白同工型的作用可能对病毒转录具有总体影响。 我们将将这一技术与亲seq和Pro-CAP相结合,以确定IE2同工型的作用和 在病毒后期转录中,UL79 LTF(推定的晚期病毒转录因子) 研究,我们将检验以下假设,即HCMV篡夺Pol II的启动和伸长控制以导致病毒 DNA复制,在裂解和潜在感染中协调病毒的基因表达程序,以及 与染色质的威胁有关。 转录和结构元素在HCMV复制起源的功能中的作用(AIM 1) 核心DNA元素和病毒因子在晚期转录中需要(AM 2); 转录在静止的IND中响应激活(AIM 3)。 Meier以及病毒学和经验丰富的价格实验室的相关和广泛的专业知识。 这项研究不能仅由任何一个实验室完成。 构建和完成该研究计划的生产性合作。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFERY L MEIER其他文献

JEFFERY L MEIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFERY L MEIER', 18)}}的其他基金

Mechanisms regulating cytomegalovirus
巨细胞病毒的调节机制
  • 批准号:
    10421243
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Mechanisms Regulating Cytomegalovirus
巨细胞病毒的调节机制
  • 批准号:
    10481050
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Control of Human Cytomegalovirus
人类巨细胞病毒的控制
  • 批准号:
    8413400
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Control of Human Cytomegalovirus
人类巨细胞病毒的控制
  • 批准号:
    8762410
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Control of Human Cytomegalovirus
人类巨细胞病毒的控制
  • 批准号:
    8243763
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Control of Human Cytomegalovirus
人类巨细胞病毒的控制
  • 批准号:
    8598021
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION
ACTG A5201 持续病毒学抑制后的阿扎那韦/利托那韦
  • 批准号:
    7604851
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
ACTG A5211 HIV-1 ENTRY INHIBITOR, SCH 417690, TO TREAT HIV INFECTED SUBJECTS
ACTG A5211 HIV-1 进入抑制剂,SCH 417690,用于治疗 HIV 感染者
  • 批准号:
    7604836
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
ACTG A5001 - AIDS LONGITUDINAL LINKED RANDOMIZED TRIALS
ACTG A5001 - 艾滋病纵向连锁随机试验
  • 批准号:
    7604800
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
ACTG A5202 & ACTG A5224S EMTRICITABINE/TENOFOVIR OR ABACAVIR/LAMIVUDINE FOR HIV
ACTG A5202
  • 批准号:
    7604863
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

ALA光动力上调炎症性成纤维细胞ZFP36抑制GADD45B/MAPK通路介导光老化皮肤组织微环境重塑的作用及机制研究
  • 批准号:
    82303993
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
YAP1-TEAD通过转录调控同源重组修复介导皮肤光老化的作用机制
  • 批准号:
    82371567
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
下丘脑乳头上核-海马齿状回神经环路在运动延缓认知老化中的作用及机制研究
  • 批准号:
    82302868
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
微纳核壳结构填充体系构建及其对聚乳酸阻燃、抗老化、降解和循环的作用机制
  • 批准号:
    52373051
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
KIAA1429介导MFAP4-m6A甲基化修饰在紫外线诱导皮肤光老化中的作用和机制研究
  • 批准号:
    82373461
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
3D 力传感鞋垫,用于可穿戴、人工智能支持的高保真步态监控
  • 批准号:
    10688715
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
An acquisition and analysis pipeline for integrating MRI and neuropathology in TBI-related dementia and VCID
用于将 MRI 和神经病理学整合到 TBI 相关痴呆和 VCID 中的采集和分析流程
  • 批准号:
    10810913
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Advanced thin-slab TOF-PET detector module for next generation of brain PET
用于下一代大脑 PET 的先进薄板 TOF-PET 探测器模块
  • 批准号:
    10719570
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
A Gesture-Powered Software Platform of Neurologic Music Therapy Games and Puzzles: To Stimulate Neuroplasticity and Prolong Functional Independence in Individuals Diagnosed with Alzheimer's Disease
神经音乐治疗游戏和谜题的手势驱动软件平台:刺激阿尔茨海默病患者的神经可塑性并延长功能独立性
  • 批准号:
    10611831
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The NIH SPAN Coordinating Center
NIH SPAN 协调中心
  • 批准号:
    10591751
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了